Dose: 100 mg
Single Dose: 100 (100)
Frequency: 24 hourly
Route: PO
Instructions:

. It is of Synthetic origin and belongs to Propanoic Acid. . The Molecular Weight of Ciprofibrate is 289.20. Its pKa is 4.6.

Ciprofibrate is contraindicated in conditions like Renal impairment,Hepatic impairment.

Ciprofibrate produces potentially life-threatening effects which include Rhabdomyolysis, Myositis. which are responsible for the discontinuation of Ciprofibrate therapy.The symptomatic adverse reactions produced by Ciprofibrate are more or less tolerable and if they become severe, they can be treated symptomatically, these include Vertigo, Tiredness, Headache, Drowsiness, Nausea, Vomiting, Diarrhea, Skin rashes, Impotence, Hair loss, Increased intracranial pressure.

Ciprofibrate is primarily indicated in conditions like Hypercholesterolaemia, Hyperlipidaemias of type IIa, IIb, III and IV in patients who have not responded adequately to diet., Hyperlipidemia, Hypertriglyceridaemia.

Ciprofibrate is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementCerivastatin SodiumCerivastatin sodium causes additive toxicity with CiprofibrateCholestyramineSimvastatinWarfarin (Na) These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Liver Function Test (LFT)

Drug should not be given to Paediatrics, Pregnant Mothers, patients suffering from Kidney dysfunction, patients suffering from Liver Malfunction, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

Tab Store at room temperature.

Clofibrate should not be given to patients with severe liver or kidney impairment, primary biliary cirrhosis, gallstone or gallbladder disorder or hypoalbuminaemic state.